Skip to main content
SpringerLink
Log in

Antipsychotika

  • Chapter
  • First Online:
Neuro-/Psychopharmaka im Kindes- und Jugendalter

  • 1306 Accesses

Zusammenfassung

Antipsychotika (früherer Begriff Neuroleptika) sind Neuro‑/Psychopharmaka, die vorrangig zur symptomatischen Behandlung von Erkrankungen aus dem schizophrenen Formenkreis eingesetzt werden sowie bei psychotischen Symptomen im Rahmen anderer Störungen (u. a. affektive oder organisch bedingte Störungen) und bei Manie. Einige werden in der Kinder- und Jugendpsychiatrie aber auch als Stimmungsstabilisatoren, bei Tic-Störungen und zudem symptomatisch bei Reizbarkeit, Agitiertheit und aggressiven Verhaltensweisen sowie Anspannung, Einschlafstörungen oder gedanklicher Einengung angewandt.

In diesem Kapitel werden die Klassifikation und Wirk(ungs)mechanismen der Antipsychotika, die in der Kinder- und Jugendpsychiatrie eingesetzt werden, besprochen und schwerpunktmäßig diejenigen pharmakologischen Aspekte von Antipsychotika dargestellt, die für klinisch tätige ärztliche Kollegen für den therapeutischen Einsatz dieser Substanzen relevant sind. Dabei wird u. a. auf Anwendungsgebiete, die klinische Wirksamkeit und die Studienlage eingegangen. Es werden Dosierungsempfehlungen gegeben und mögliche unerwünschte Arzneimittelwirkungen und -wechselwirkungen behandelt. Das Kapitel schließt mit Empfehlungen zur Behandlungsdauer sowie zu notwendigen Kontrolluntersuchungen im Rahmen der Pharmakotherapie mit Antipsychotika.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 149.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • AACAP Official Action (2001) Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Psy 40(Suppl):4–S23

    Google Scholar 

  • Al-Dhaher Z, Kapoor S, Saito E et al. (2016) Activating and tranquilizing effects of first-time treatment with aripiprazole, olanzapine, quetiapine, and risperidone in youth. J Child Adolesc Psychopharmacology 26:458–470

    Article  CAS  Google Scholar 

  • Aman MG, Mcdougle CJ, Scahill L et al. (2009) Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. J Am Acad Child Psy 48:1143–1154 (for the Research Units on Pediatric Psychopharmacology Autism Network)

    Article  Google Scholar 

  • Amato D, Canneva F, Cumming P et al. (2020) A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. Mol Psychiatry 25:2101–2118

    Article  CAS  PubMed  Google Scholar 

  • Amor LB (2012) Antipsychotics in pediatric and adolescent patients: a review of comparative safety data. J Affect Disorders 138:22–S30

    Article  Google Scholar 

  • Ayanthi AR, Hickman IJ, Wang AYH et al. (2006) Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum. J Clin Psychopharm 26:232–237

    Article  Google Scholar 

  • Bai YH, Liu TB, Xu AH, Yang HC, Gao KM (2019) Comparison of common side effects from mood stabilizers and antipsychotics between pediatric and adult patients with bipolar disorder: a systematic review of randomized, double-blind, placebo-controlled trials. Expert Opin Drug Safety 18:703–717

    Article  Google Scholar 

  • Baptista T, Kin Y, Beaulieu S, de Baptista EA (2002) Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 35:205–219

    Article  CAS  PubMed  Google Scholar 

  • Benes FM (2009) Neural circuitry models of schizophrenia: Is it dopamine, GABA, glutamate, or something else? Biol Psychiat 65:1003–1005

    Article  PubMed  Google Scholar 

  • Bernagie C, Danckaerts M, Wampers M, De Hert M (2016) Aripiprazole and acute extrapyramidal symptoms in children and adolescents: a meta-analysis. CNS Drugs 30:807–818

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brannan SK, Sawchak S, Miller AC et al. (2021) Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. New Engl J Med 384:717–726

    Article  CAS  PubMed  Google Scholar 

  • Brown AS (2011) The environment and susceptibility to schizophrenia. Prog Neurobiol 93:23–58

    Article  CAS  PubMed  Google Scholar 

  • Calarge CA, Burns TL, Schlechte JA, Zemel BS (2015) Longitudinal examination of the scelettal effects of selective serotonin reuptake inhibitors an risperidone in boys. J Clin Psychiatry 76:607–613

    Article  PubMed  PubMed Central  Google Scholar 

  • Campbell M, Small AM, Green WH et al. (1984) A comparison of haloperidol and lithium in hospitalized aggressive conduct disordered children. Arch Gen Psychiat 41:650–656

    Article  CAS  PubMed  Google Scholar 

  • Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140–144

    Article  CAS  Google Scholar 

  • Carpenter WT, Davis JM (2012) Perspective. Another view of the history of antipsychotic drug discovery and development. Mol Psychiatr 17:1168–1173

    Article  CAS  Google Scholar 

  • Ceraso A, Lin JJ, Schneider-Thoma J et al. (2020) Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 11:Cd8016

    Google Scholar 

  • Chandradasa M, Ruwanpriya S, de Silva S, Rathnayake L, Kuruppuarachchi K (2022) Randomised, placebo-controlled trial on topiramate add-on therapy for weight reduction and symptomatology in overweight/obese persons with schizophrenia. Asian J Psychiatr 68:102963. https://doi.org/10.1016/j.ajp.2021.102963

    Article  PubMed  Google Scholar 

  • Chang C-Y, Luo D-Z, Pei J-C et al. (2021) Not just a bystander: The emerging role of astrozytes and research tools in studying cognitive dysfunctions in schizophrenia. Int J Mol Sci 22:5343. https://doi.org/10.3390/ijms22105343

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cohen D, Huinink S (2007) Atypical antipsychotic-induced diabetes mellitus in child and adolescent psychiatry. CNS Drugs 21:1035–1038

    Article  PubMed  Google Scholar 

  • Comai S, Tau M, Pavlovic Z, Gobbi G (2012) The psychopharmacology of aggressive behavior: a translational approach. Part 2: Clinical studies using atypical antipsychotics, anticonvulsants, and lithium. J Clin Psychopharm 32:237–260

    Article  CAS  Google Scholar 

  • Correll CU (2008) Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Psy 47:9–20

    Article  Google Scholar 

  • Correll CU (2011) Antipsychotic agents: traditional and atypical. In: Martin A, Scahill L, Kratochvil (Hrsg) Pediatric psychopharmacology. Principles and practise, 2. Aufl. University Press, Oxford New York, S 312–337

    Google Scholar 

  • Correll Ch, Carlson HE (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Psy 45:771–791

    Article  Google Scholar 

  • Correll CU, Kane JM (2007) One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol 17:647–655

    Article  PubMed  Google Scholar 

  • Correll CU, Sheridan EM, DelBello MP (2010) Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 12:116–141

    Article  CAS  PubMed  Google Scholar 

  • Correll CU, Kratochvil CJ, March JS (2011) Development in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics. J Clin Psychiat 72:655–670

    Article  Google Scholar 

  • Correll CU, Kohegy E, Zhao C (2017) Oral aripiprazole as maintenance treatment in adolsescent schizophrenia: results from a 52-week, randomized, placebo-controlles withdrawal study. J Am Acad Child Adolesc Psychiatry 56:784–792

    Article  PubMed  Google Scholar 

  • Correll CU, Litman RE, Filts Y et al. (2020a) Efficacy and safety of once monthly Risperidone ISM in schizophrenic patients with acute exacerbation. Schizophrenia 6:37

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Correll CU, Sikich L, Reeves G et al. (2020b) Metformin add-on vs. Antipsychotic switch vs. Continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the IMPACT trial. World Psychiatry 19:69–80

    Article  PubMed  PubMed Central  Google Scholar 

  • Coustals N, Ménard ML, Cohen D (2020) Aripiprazole in children and adolescents. J Child Adolesc Psychopharmacol 20:1–29

    Google Scholar 

  • Creese I, Burt DR, Snyder SH (1976) Dopamine receptors binding predicts clinical potencies of antischizophrenic drugs. Science 192:481–483

    Article  CAS  PubMed  Google Scholar 

  • DeNayer A, DeHert M, Scheen A, Van Gaal L, Peuskens J (2007) Belgian consensus on metabolic problems associated with atypical antipsychotics. Encephale 33:197–202

    Article  CAS  Google Scholar 

  • DelBello MP, Goldman R, Philips D et al. (2017) Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo controlled study. J Am Acad Child Adolesc Psychiatry 56:1015–1025

    Article  PubMed  Google Scholar 

  • Dietmaier O, Laux G (2020) Weiterbildungs-Curriculum Pschopharmakologie/Pharmakotherapie. Teil 15: Kombinationstherapien, Interaktionen. Psychopharmakotherapie 27:295–305

    Google Scholar 

  • Ebdrup BH, Knop FK (2021) Weight gain on antipsychotics - A perfect storm of complex pathophysiology and psychopharmacology. Acta Psychiatr Scand 144:521–523

    Article  PubMed  Google Scholar 

  • Egberts K, Mehler-Wex C, Gerlach M (2011) Therapeutic drug monitoring in child and adolescent psychiatry. Pharmacopsychiatry 44:249–253

    Article  CAS  PubMed  Google Scholar 

  • Eggers C, Roepcke B (2007) Schizophrenie, schizotype und wahnhafte Störungen (F2). In: Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie, Bundesarbeitsgemeinschaft Leitender Klinikärzte für Kinder- und Jugendpsychiatrie, Psychotherapie und Bundesverband der Ärzte für Kinder- und Jugendpsychiatrie und Psychotherapie (Hrsg) Leitlinien zu Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter, 3. Aufl. Deutscher Ärzte-Verlag, Köln, S 33–43

    Google Scholar 

  • Eggers C, Rothenberger A, Berghaus U (1988) Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psy Clin N 237:223–229

    CAS  Google Scholar 

  • Ellul P, Delorme R, Cortese S (2018) Metformin for weight gain associated with second generation antipsychotics in children and adolescents: a systematic review and meta-analysis. CNS Drugs 32:1103–1112

    Article  CAS  PubMed  Google Scholar 

  • FDA (2016) FDA warns about rare but serious skin reactions with mental health drug olanzapine. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-rare-serious-skin-reactions-mental-health-drug (Erstellt: 10. Mai 2016)

  • Findling RK, Cavus I, Pappadopulos E et al.(2013) Ziprasidone in adolescents with schizophrenia: Results from a placebo-controlled efficacy and long-term open-extension study. J Child Adoles Psychopharmacol 23:531-544

    Article  CAS  Google Scholar 

  • Findling RL, Landbloom RP, Mackle M et al. (2015a) Safety and efficacy from an 8 week double-blind trial and a 26 week open label extension of asenapine in children and adolescents with schizophrenia. J Child Adolesc Psychopharmacol 25:384–396

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Findling RL, Landbloom RL, Szegedi et al. (2015b) Asenapine for the acute treatment of pediatric manic or mixed episode of bipolar I disorder. J Am Acad Child Adolesc Psychiatry 54:1032–1041

    Article  PubMed  Google Scholar 

  • Fleischhaker Ch, Heiser P, Hennighausen K et al. (2008) Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. J Neural Transm 115:1599–1608

    Article  CAS  PubMed  Google Scholar 

  • Fountoulakis KN, Moeller HJ, Kasper S et al. (2021) The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. CNS Spectr 26:562–586

    Article  Google Scholar 

  • Fraguas D, Correll CU, Merchán-Naranjo J et al. (2011) Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharm 21:621–645

    Article  CAS  Google Scholar 

  • Friedrich ME, Winkler D, Konstantinidis A et al. (2020) Cardiovascular adverse reactions during antipsychotic treatment: results of AMSP, a drug surveillance program between 1993 and 2013. Int J Psychopharmacol 23:67–75

    CAS  Google Scholar 

  • Galling B, Roldán A, Nielsen RE et al. (2016) Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry 73:247–259

    Article  PubMed  Google Scholar 

  • Galling B, Roldán A, Hagi K et al. (2017) Antipsychotic augementation versus monotherapy in schiziphrenia: a systematic review, meta-analysis und meta-regression analysis. World Psychiatry 16:77–89

    Article  PubMed  PubMed Central  Google Scholar 

  • Gebicke-Haerter PJ (2012) Epigenetics of schizophrenia. Pharmacopsychiatry 45(Suppl 1):S42–S48

    CAS  PubMed  Google Scholar 

  • Gerlach M (2021) Pharmakologische und rechtliche Grundkenntnisse der Psychopharmakotherapie. Psych Up2date 15:71–84

    Article  Google Scholar 

  • Gerlach M, Hünnerkopf R, Rothenhöfer S et al. (2007) Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry 40:72–76

    Article  CAS  PubMed  Google Scholar 

  • Giessing Jensen K, Juul K, Fink-Jensen A, Correll CU (2015) Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychaitry 54:25–36

    Article  Google Scholar 

  • Glassman AH, Bigger Th (2001) Antipsychotic drugs: Prolonged QTc interval, torsade de pointes and sudden death. Am J Psychiat 158:1774–1782

    Article  CAS  PubMed  Google Scholar 

  • Goedhard LE, Stolker JJ, Herrdink ER et al. (2006) Pharmacotherapy of aggressive behavior in general adult psychiatry: A systematic review. J Clin Psychiat 67:1013–1024

    Article  CAS  Google Scholar 

  • Goldman R, Loebel A, Cucchiaro J (2017) Efficacy and safety of lurasidone in adolescents with schizophrenia: a six-week, randomized placebo controlled study. J Child Adolesc Psychopharmacol 27:516–525

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Goldstein BI, Sassi R, Diler RS (2012) Pharmacological treatment of bipolar disorder in children and adolescents. Child Adolesc Psychiatr Clin N 21:911–939

    Article  Google Scholar 

  • Grohmann R, Hippius H, Rüther R (2001) Extrapyramidal motor side-effects and blood profile changes. Stumbling blocks in psychiatric pharmacotherapy. MMW Fortschr Med 77(Suppl 2):76–77

    Google Scholar 

  • Guber KM, Cortes ND, Duan L (2021) Risk of obesity among children prescribes atypical antipsychotics for six months or more. J Child Adolesc Psychiatry. https://doi.org/10.1089/cap.2021.0021

    Article  Google Scholar 

  • Guinart D, Taipale H, Rubio JM et al. (2021) Risk Factors, incidence, and outcomes of neuroleptic malignant syndrome on long-acting injectable vs oral antipsychotics in a nationwide schizophrenia cohort. Schizophr Bull 476:1621–1623

    Article  Google Scholar 

  • Haase HJ (1954) About prevalence and interpretation of the psychomotor Parkinson syndrome in megaphen or largactil treatment duration. Nervenarzt 25:486–492

    CAS  PubMed  Google Scholar 

  • Haase HJ, Janssen PAJ (1965) The action of neuroleptic drugs. Year Book Medical, Chicago

    Google Scholar 

  • Hasan A, Falkai P, Wobrock T et al. (2015) World Federation of Societis of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry 16:142–170 (on behalf of the WFSBP Task Force on Treatment Guidelines for Schizophrenia)

    Article  PubMed  Google Scholar 

  • Häßler F, Dück A, Jung M, Reis O (2014) treatment of aggressive behavior problems in boys with intellectual disabilities using zuclopenthixol. J Child Adolesc Psychopharmacol 24:579–581

    Article  PubMed  Google Scholar 

  • Heck J, Krichewsky B, Krause O et al. (2021) Photosensibilisierung durch Psychopharmaka und andere Arzneimittel. Psychopharmakotherapie 28:94–101

    Google Scholar 

  • Henderson DC, Cagliero E, Copeland PM et al. (2007) Elevated hemoglobin A1c as possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atipycal antipsychotics. J Clin Psychiat 68:533–541

    Article  CAS  Google Scholar 

  • Hiemke C, Pfuhlmann B (2012) Interactions and monitoring of antipsychotic drugs. Handb Exp Pharmacol 212:241–265

    Article  CAS  Google Scholar 

  • Hiemke C, Bergemann N, Clement HW et al. (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology - Update 2017. Pharmacopsychiatry 51:9–62

    Article  CAS  PubMed  Google Scholar 

  • Højlund M, Kemp AF, Haddad PM et al. (2021) Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Lancet Psychiatry 8:471–486

    Article  PubMed  Google Scholar 

  • Howes O, McCutcheon R, Stone J (2015) Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol 29:97–115

    Article  PubMed  PubMed Central  Google Scholar 

  • Howes OD, McCutcheon R, Owen MJ, Murray RM (2017) The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry 81:9–20

    Article  CAS  PubMed  Google Scholar 

  • Huber M, Schlosser-Weber G, Paeschke N, Broich K (2015) Antipsychotika in der Schwangerschaft. Psychopharmakotherapie 22:278–285

    Google Scholar 

  • Huhn M, Nikolakopoulou A, Schneider-Thoma J et al. (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394:939–951

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Huybrechts KF, Hernandez-Diaz S, Patorno E et al. (2016) Antipsychotic use in pregnancy and the risk of congenital malformations. JAMA Psychiatry 73:938–946

    Article  PubMed  PubMed Central  Google Scholar 

  • Jensen KG, Juul K, Fink-Jensen A, Correll CU, Pagsberg AK (2015) Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry 54:25–36

    Article  PubMed  Google Scholar 

  • Kaar SJ, Natesan S, McCutcheon R, Howes OD (2020) Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2019.107704

    Article  PubMed  Google Scholar 

  • Kapur S, Seeman P (2000) Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatr Neurosci 25:161–166

    CAS  Google Scholar 

  • Kapur S, Seeman P (2001) Does fast dissociation from the dopamine D2 receptor explaine the action of atypical antipsychotics? A new hypothesis. Am J Psychiat 158:360–369

    Article  CAS  PubMed  Google Scholar 

  • Keefe RSE, Bilder RM, Davis SM et al. (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiat 64:633–647 (CATIE investigators and the Neurocognitive Working Group)

    Article  CAS  PubMed  Google Scholar 

  • Kegeles LS, Slifstein M, Frankle WG et al. (2008) Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology 33:3111–3125

    Article  CAS  PubMed  Google Scholar 

  • Keks N, Hope J, Schwartz D et al. (2020) Comparative tolerability of dopamine D2/3 receptor partial agonists for schizophrenia. CNS Drugs 34:473–450

    Article  CAS  PubMed  Google Scholar 

  • Kennedy WK, Jann MW, Kutscher EC (2013) Clinically significant drug interactions with atypical antipsychotics. CNS Drugs 27:1021–1048

    Article  CAS  PubMed  Google Scholar 

  • Khandaker GM, Zimbron J, Dalman C, Lewis G, Jones PB (2012) Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. Schizophr Res 139:161–168

    Article  PubMed  PubMed Central  Google Scholar 

  • Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU (2019) Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-tohead comparisons. World Psychiatry 18:208–224

    Article  PubMed  PubMed Central  Google Scholar 

  • Klampfl K, Taurines R, Preuss A et al. (2010) Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. Pharmacopsychiatry 43:58–65

    Article  CAS  PubMed  Google Scholar 

  • Koblan KS, Kent J, Hopkins SC et al. (2020) A non-D2-receptor-binding drug for the treatment of schizophrenia. New Engl J Med 382:1497–1506

    Article  CAS  PubMed  Google Scholar 

  • Köster L-S, Carbon M, Correll CU (2014) Emerging drugs for schizophrenia: an update. Expert Opin Emerg Drugs 19:511–531

    Article  PubMed  Google Scholar 

  • Koller E, Schneider B, Bennett K, Dubitsky G (2001) Clozapine-associated diabetes. Am J Med 111:716–723

    Article  CAS  PubMed  Google Scholar 

  • Koller EA, Cross JT, Schneider B (2004a) Risperidone-associated diabetis mellitus in children. Pediatrics 113:421–422

    Article  PubMed  Google Scholar 

  • Koller EA, Weber J, Doraiswamy PM, Schneider BS (2004b) A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiat 65:857–863

    Article  CAS  Google Scholar 

  • Kornhuber J, Thome J, Riederer P (1998) Modellvorstellungen zur Ätiopathogenese der Schizphrenien. In: Riederer P, Laux G, Pöldinger W (Hrsg) Neuroleptika, 2. Aufl. Neuro-Psychopharmaka. Ein Therapie-Handbuch, Bd. 4. Springer, Wien, S 3–21

    Google Scholar 

  • Koskuvi M, Lehtonen S, Trontti K et al. (2022) Contribution of astrocytes and clinical manifestation of schizophrenia. Glia 70:650–660

    Article  CAS  PubMed  Google Scholar 

  • Kulkarni SK, Naidu PS (2003) Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drug Today 39:19–49

    Article  CAS  Google Scholar 

  • Labad J, Montalvo I, Gonzalez-Rodriguez A et al. (2020) Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinemia: a systematic review and meta-analysis. Schizophr Res 222:88–96

    Article  PubMed  Google Scholar 

  • Laruelle M (2014) Schizophrenia: from dopaminergic to glutamatergic interventions. Curr Opin Pharmacol 14:97–102

    Article  CAS  PubMed  Google Scholar 

  • Lee SE, Kronsberg H, Findling RL (2020) Psychopharmacologic treatment of schizophrenia in adolsecents and children. Child Adolesc Psychiatr Clin N Am 29:183–210

    Article  PubMed  Google Scholar 

  • Lessig MC, Shapira NA, Murphy TK (2001) Topiramate reversing atypical antipsychotic weight gain. Letter J Am Acad Child Psy 40:1364

    Article  CAS  Google Scholar 

  • Leucht S, Corves C, Arbter D et al. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31–41

    Article  CAS  PubMed  Google Scholar 

  • Li A, Zalesky A, Yue W et al. (2020) A neuroimaging biomarker for striatal dysfunction in schizophrenie. Nat Med 26:558-565

    Article  CAS  PubMed  Google Scholar 

  • Libowitz MR, Nurmi EL (2021) The burden of antipsychotic-induced weight gain and metabolic syndrome in children. Front Psychiatry 12:623681 https://doi.org/10.3389/fpsyt.2021.623681

    Article  PubMed  PubMed Central  Google Scholar 

  • Lieberman JA (2004) Dopamine partial agonists. A new class of antipsychotics. CNS Drugs 18:251–267

    Article  CAS  PubMed  Google Scholar 

  • Liu HY, Potter MP, Woodworth KY et al. (2011) Pharmcologic treatments for pediatric bipolar disorder: a review and meta-analysis. J Am Acad Child Psy 50:749–762

    Article  Google Scholar 

  • Loebel A, Brams M, Goldman R et al. (2016) Lurasidone for the treatment of irritability associated with autistic disorder. J Autism Dev Disord 46:1153–1163

    Article  PubMed  Google Scholar 

  • López-Muñoz F, Alamo C, Cuenca E et al. (2005) History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry 17:113–135

    Article  PubMed  Google Scholar 

  • Madaan V, Dvir Y, Wilson DR (2008) Child and adolescent schizophrenia: pharmacological approaches. Exp Opin Pharmacol 9:2053–2068

    Article  CAS  Google Scholar 

  • Man KKC, Shao SC, Chang YC et al. (2021) Cardiovascular and metabolic risk of antipsychotics in children and young adults: A multinational self-controlled case series study. Epidem Psychiatr Sci 30:e65. https://doi.org/10.1017/s2045796021000494

    Article  Google Scholar 

  • Marenco S, Weinberger DR (2000) The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev Psychopathol 12:501–527

    Article  CAS  PubMed  Google Scholar 

  • Martin WF, Correll CU, Weiden PJ et al. (2019) Mitigation of olanzapine-induced weight gain with samidorphan, an opioid antagonist: a randomized double-blind phase 2 study in patients with schizophrenia. Am J Psychiatry 176:457–467

    Article  PubMed  Google Scholar 

  • Masi G, Liboni F (2011) Management of schizophrenia in children and adolescents. Drugs 71:179–208

    Article  CAS  PubMed  Google Scholar 

  • McCutcheon RA, Abi-Dargham A, Howes OD (2019) Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci 42:205–220

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mishara AL, Goldberg TE (2004) A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: Opening a closed book. Biol Psychiat 55:1013–1022

    Article  CAS  PubMed  Google Scholar 

  • Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79–104

    Article  CAS  PubMed  Google Scholar 

  • Möller HJ, Müller WE, Bandelow B (2001) Neuroleptika. Pharmakologische Grundlagen, klinisches Wissen und therapeutisches Vorgehen. Wissenschaftliche Verlagsgesellschaft, Stuttgart, S 243

    Google Scholar 

  • Müller WE (2019) Vergleichende Betrachtung der pharmakologischen Eigenschaften von Dopamin-D2-Partialagonisten. Psychopharmakotherapie 26:192–204

    Google Scholar 

  • Munawar N, Ahsan K, Muhammad K et al. (2021) Hidden role of gut microbiome dysbiosis in schizophrenia: antipsychotics or psychobiotics as therapeutics? Int J Mol Sci 22:7671. https://doi.org/10.3390/ijms22147671

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Morrison JA, Cottingham EM, Barton BA (2002) Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiat 159:655–657

    Article  PubMed  Google Scholar 

  • Naguy A, Adel T, Almazeedi I (2019) Paliperidone use in child psychiatry: evidence or diffidence? Pharmacology 104:67–70

    Article  CAS  PubMed  Google Scholar 

  • Nevels RM, Dehon EE, Alexander K, Gontkovsky ST (2010) Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: A review of current and potentially promising treatment options. Exp Clin Psychopharm 18:184–201

    Article  Google Scholar 

  • Onishi Y, Mikami K, Kimoto K et al. (2021) Second-generation antipsychotic drugs for children and adolescents. Review. J Nippon Med Sch 88:10–16

    Article  PubMed  Google Scholar 

  • Pagsberg AK, Tarp S, Glintborg D et al. (2017) Acute antipsychotic treatment with schizophrenia spectrum disorders: a systematic review and network meta-analysis. J Am Acad Child Adolesc Psychiatry 56:191–202

    Article  PubMed  Google Scholar 

  • Patteet L, Morrens M, Maudens KE et al. (2012) Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit 34:629–651

    Article  CAS  PubMed  Google Scholar 

  • Pillay J, Boylan K, Newton A et al. (2018) Harms of antipsychotics in children and adolescents: a systematic review update. Can J Psychiatry 63:661–678

    Article  PubMed  PubMed Central  Google Scholar 

  • Pozzi M, Ferrentino RI, Scrinzi C et al. (2020) Weight and body mass index increase in children and adolescents exposed to antipsychotic drugs in non-interventional settings: a meta-analysis and meta-regression. Eur J Child Adolesc Psychiatry. https://doi.org/10.1007/s00787-020-01582-9

    Article  Google Scholar 

  • Pringsheim T, Gorman D (2012) Second-generation antipsychotics for the treatment of disruptive behaviour disorders in children: a systematic review. Can J Psychiat 57:722–727

    Article  Google Scholar 

  • Pringsheim T, Lam D, Ching H, Patten S (2011) Metabolic and neurological complications of second-generation anti-psychotic use in children. Drug Saf 34:651–668

    Article  PubMed  Google Scholar 

  • Rahman T, Sahrmann JM, Olsen MA et al. (2022) Risk of breast cancer with prolactin elevating antipsychotic drugs: an observational study of US women (Ages 18-64 years). J Clin Psychopharmacol 42:7–16

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Razjouyan K, Danesh A, Khademi M, Davari-Ashtiani R, Noorbaksh S (2018) A comparative study of risperidone and aripiprazole in attention deficit hyperactivity disorder in children under six years old. A randomized double-blind study. Iran J Pediatr 28:e60087

    Article  Google Scholar 

  • Remington G, Hahn MK, Agarwal SM, Chintoh A (2021) Schizophrenia: Antipsychotics and drug development. Behav Brain Res 414:113507. https://doi.org/10.1016/j.bbr.2021.113507

    Article  CAS  PubMed  Google Scholar 

  • Reyad AA, Mishriky R (2019) Asenapine: Pharmacological aspects and role in psychiatric disorders. Psychiatr Danube 31:157–161

    Article  CAS  Google Scholar 

  • Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M (2006) A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiat 163:402–410

    Article  PubMed  Google Scholar 

  • Robb AS, Carson WH, Nyilas M et al. (2010) Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: Post-hoc analysis of randomized clinical trial data. J Child Adol Psychop 20:33–38

    Article  Google Scholar 

  • Sallee F, Kohegy E, Zhao J et al. (2017) Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole fort he treatment of Tourette’s disorder in children and adolescents. J Child Adolesc Psychopharmacol 27:771–781

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sallee FR, Kurlan R, Goetz CG et al. (2000) Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Psy 39:292–299

    Article  CAS  Google Scholar 

  • Scahill L, Lechman JF, Schultz RT, Katsovich L, Peterson BS (2003) A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130–1135

    Article  CAS  PubMed  Google Scholar 

  • Schatzberg AF, Cole JO, De Battista C (2003) Manual of clinical psychopharmacology, 4. Aufl. American Psychiatric Publishing, Washington

    Google Scholar 

  • Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU (2013) Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. Curr Opin Psychiatr 26:219–230

    Article  Google Scholar 

  • Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511:421–427

    Article  PubMed Central  Google Scholar 

  • Seeman MV (2021) History of the dopamine hypetric Dothesis of antipsychotic action. World J Psychiatr 11:355–364

    Article  PubMed  PubMed Central  Google Scholar 

  • Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiat 47:27–38

    Article  Google Scholar 

  • Seeman P, Lee T (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188:1217–1219

    Article  CAS  PubMed  Google Scholar 

  • Seida JC, Schouten JR, Boylan K et al. (2012) Antipsychotics for children and youth adults: A comparative effectiveness review. Pediatrics 129:e771–e784

    Article  PubMed  Google Scholar 

  • Shao P, Ou JJ, Peng M et al. (2015) Effects of clozapine and other atypical antipsychotics on infants development who were exposed to as fetus: a post-hoc analysis. Plos One 10:4 (Article Nr. e0123373)

    Google Scholar 

  • Shapiro M, Reid A, Olsen B (2016) Topiramate and zonisamide and weight loss in children and adolscents prescribed psychiatric medications. Int J Psychiatry Med 51:56–68

    Article  PubMed  Google Scholar 

  • Siafis S, Wu H, Wang DF et al. (2023) Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Mol Psychiatry. https://doi.org/10.1038/s41380-023-02203-y

    Article  PubMed  PubMed Central  Google Scholar 

  • Silva RR, Munoz DM, Alpert M, Perlmutter IR, Diaz J (1999) Neuroleptic malignant syndrome in children and adolescents. J Am Acad Child Psy 38:187–194

    Article  CAS  Google Scholar 

  • Singappuli P, Sonuga-Barke E, Kyriakopoulos M (2021) Antipsychotic long-term treatment in children und young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions. CNS Spectr. https://doi.org/10.1017/s1092852921000523

    Article  PubMed  Google Scholar 

  • Singh J, Robb A, Vijapurkar U, Nuamah I, Hough D (2011) A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry 70:1179–1188

    Article  CAS  PubMed  Google Scholar 

  • Smith RC, Maayan L, Wu R et al. (2018) Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. Psychopharmacology 235:3545–3558

    Article  CAS  PubMed  Google Scholar 

  • Solmi M, Pigato G, Kane JM, Correll CU (2018) Clinical risk factors for the development of tardive dyskinesia. J Neurol Sciences 389:21–27

    Article  Google Scholar 

  • Spencer EK, Kafantaris V, Padron-Gayol MV, Rosenberg CR (1992) Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull 28:183–186

    CAS  PubMed  Google Scholar 

  • Stentjeberg-Olesen M, Ganocy S, Findling R et al. (2015) Early response or non-response at week 2 and week 3 predict ultimate response or non-response in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial. Eur Child Adolesc Psychiatry 24:1485–1496

    Article  Google Scholar 

  • Stigler KA, Potenza MN, Posey DJ, McDougle CJ (2004) Weight gain associated with atypical antipsychotic use in children and adolescents. Prevalence, clinical relevance, and management. Pediatr Drugs 6:33–44

    Article  Google Scholar 

  • Szatmari B, Barabassy A, Harsanyi J et al. (2020) Cariprazine safety in adolescents and the elderly: analysis of clinical study data. Front Psychiatry 11:61. https://doi.org/10.3389/fpsyt.2020.00061

    Article  PubMed  PubMed Central  Google Scholar 

  • S3-Leitlinie Schizophrenie (2019) https://www.awmf.org/uploads/tx_szleitlinien/038-009k_S3_Schizophrenie_2019-03.pdf

  • Tamminga CA (2006) Principles of pharmacology of schizophrenia. In: Charney DS, Nestler (Hrsg) Neurobiology of mental illnesses, 2. Aufl. Oxford University Press, Oxford, S 339–354

    Google Scholar 

  • Tickell AM, Rohleder C, Ho NI et al. (2021) Identifying pathways to early-onset metabolic dysfunction, insulin resistance and inflammation in young adult inpatients with emerging affective and major mood disorders. Early Interv Psychiatry 16:1121–1129

    Article  PubMed  Google Scholar 

  • Vancampfort D, Firth J, Correll CU et al. (2019) The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of Metaanalyses of randomized controlled trials. World Psychiatry 18:53–66

    Article  PubMed  PubMed Central  Google Scholar 

  • Vazquez-Bourgon J, Alario MI, Mayoral van Son J et al. (2020) A 3-year prospective study on the metabolic effect of aripiprazol, quetiapin and ziprasidone: a pragmatic clinical trial in first episode psychosis patients. Eur Neuropsychopharmacol 39:46–55

    Article  CAS  PubMed  Google Scholar 

  • Vieta E, Montes E (2018) A review of asenapine in the treatment of bipolar disorder. Clin Drug Invest 38:87–99

    Article  CAS  Google Scholar 

  • Wagner E, Hasan A (2018) Cariprazin – eine neue medikamentöse Therapieoption in der Schizophreniebehandlung. Psychopharmakotherapie 25:278–285

    Google Scholar 

  • Weizman S, Shelef A, Bris EB, Stryjer R (2021) A double-blind, placebo-controlled trial of bupropion add-on to olanzapine in overweight individuals with schizophrenia. J Clin Psychopharmacology 41:629-631

    Article  CAS  Google Scholar 

  • Wolkin A, Barouche F, Wolf A et al. (1989) Dopamine blockade and clinical response for two biological subgroups of schizophrenia. Am J Psychiatry 146:905–908

    Article  CAS  PubMed  Google Scholar 

  • Wu QQ, Huang J, Wu RR (2021) Drugs based on NMDAR hypofunction hypothesis in schizophrenia. Front Neurosci 15:641047. https://doi.org/10.3389/fnins.2021.641047

    Article  PubMed  PubMed Central  Google Scholar 

  • Yee CS, Bahji A, Lolich M, Vazquez GH, Baldessarini RJ (2022) Comparative efficacy and tolerability of antipsychotics for juvenile psychotic disorders: a systematic review and network meta-analysis. J Clin Psychopharmacol 42:198–208

    Article  PubMed  Google Scholar 

  • Zhao MJ, Qin B, Wang JB et al. (2018) Efficacy and acceptibility of cariprazine in acute exacerbation schizophrenia meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 38:55-59

    Article  CAS  PubMed  Google Scholar 

  • Zuddas A, Zanni R, Usala T (2011) Second generation antipsychotics (SGas) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharm 21:600–620

    Article  CAS  Google Scholar 

Quellen und weiterführende Literatur

Download references

Author information

Authors and Affiliations

  1. Privatklinik für Seelische Gesundheit, Jugendliche und junge Erwachsene, HEMERA Klinik, Bad Kissingen, Deutschland

    Prof. Dr. med. Claudia Mehler-Wex

  2. Zentrum für Psychische Gesundheit, Universitätsklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Würzburg, Deutschland

    Prof. Dr. med. Timo D. Vloet

  3. Hammelburg, Deutschland

    Prof. Dr. rer. nat. Manfred Gerlach

Authors
  1. Prof. Dr. med. Claudia Mehler-Wex
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Timo D. Vloet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. rer. nat. Manfred Gerlach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudia Mehler-Wex .

Editor information

Editors and Affiliations

  1. Hammelburg, Deutschland

    Manfred Gerlach

  2. Privatklinik für Seelische Gesundheit, Jugendliche und junge Erwachsene, HEMERA Klinik, Bad Kissingen, Deutschland

    Claudia Mehler-Wex

  3. Zentrum für Psychische Gesundheit, Universitätsklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie, Würzburg, Deutschland

    Marcel Romanos

  4. Klinik für Kinder- und Jugendpsychiatrie und Psychotherapie, Psychiatrische Universitätsklinik Zürich, Zürich, Schweiz

    Susanne Walitza

  5. KIRINUS Tagesklinik Nymphenburg, München, Deutschland

    Christoph Wewetzer

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mehler-Wex, C., Vloet, T.D., Gerlach, M. (2023). Antipsychotika. In: Gerlach, M., Mehler-Wex, C., Romanos, M., Walitza, S., Wewetzer, C. (eds) Neuro-/Psychopharmaka im Kindes- und Jugendalter. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-65267-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-65267-1_6

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-65266-4

  • Online ISBN: 978-3-662-65267-1

  • eBook Packages: Psychology (German Language)

Publish with us

Policies and ethics

Search

Navigation